Colorado-based Colibri alleged in a 2020 lawsuit that Medtronic's Evolut devices for replacing heart valves in heart disease patients infringed a Colibri patent related to deploying artificial ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut™ ...

The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients. These patients had a ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut ...

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients ...

The Evolut Low Risk Trial was a randomized, multicenter, international study assessing the safety and efficacy of the Evolut TAVR system versus surgery in low-risk patients.

Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve performance and clinical outcomes than those undergoing surgery.

Medtronic announced new data from its CoreValve Evolut clinical program supporting the transcatheter aortic valve replacement (TAVR) system.

ATLANTA and DUBLIN, May 20, 2024 /PRNewswire/ -- Medtronic, the global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral ...